Chabrera Carolina, Font Albert, Caro Mónica, Areal Joan, Zabalegui Adelaida
Author Affiliations: School of Health Science-TecnoCampus, Department of Nursing, University Pompeu Fabra, Mataró (Ms Chabrera); Department of Oncology, Catalan Institute of Oncology, Badalona (Ms Chabrera and Dr Font); Department of Radiation Oncology, Oncology Catalan Institute, Badalona (Dr Caro); Department of Urology, Germans Trias i Pujol University Hospital, Badalona (Dr Areal); and Hospital Clinic, Barcelona, Spain (Dr Zabalegui).
Cancer Nurs. 2015 Jan-Feb;38(1):E55-60. doi: 10.1097/NCC.0000000000000140.
Decision aids (DAs) have been developed in several health disciplines to support decision making informed by evidence, such as the benefits and risks of different treatment options. Decision aids can improve the decision-making process by reducing decisional conflict and helping patients to participate in decision making.
The aim of this study was to design and develop a DA for treatment decision making in localized prostate cancer in Spain with regard to surgery, radiotherapy, or watchful waiting.
INTERVENTIONS/METHODS: We developed a DA based on the principles of the International Patient Decision Aid Standards Collaboration and according to the Ottawa Decision Support Framework. The structural development process involved DA developers, expert feedback, use of the Delphi method, and patient feedback. We conducted a pilot test on 34 men with localized prostate cancer.
The DA is a structured booklet. According to the International Patient Decision Aid Standards checklist, the DA scored 22 of 27 points (81.48%). The development process section scored 22 of 24 points (91.6%), and the effectiveness of the decision-making process section scored 6 of 6 (100%). The clinical pilot test yielded positive feedback regarding the design, images, understandability, usability, explanations, and amount of information in the DA.
We developed a Spanish DA with a strong quality score to help patients make an informed choice regarding their prostate cancer treatment. Future research will assess the impact of the DA and its association with improved decision making.
This tool provides information about the risks and benefits of different treatment options and helps patients to understand the importance of their own values for informing treatment choices.
在多个健康领域已开发出决策辅助工具(DAs),以支持基于证据的决策制定,例如不同治疗方案的益处和风险。决策辅助工具可通过减少决策冲突并帮助患者参与决策制定来改善决策过程。
本研究的目的是设计并开发一种用于西班牙局限性前列腺癌治疗决策的决策辅助工具,涉及手术、放疗或观察等待。
干预措施/方法:我们基于国际患者决策辅助标准协作的原则并根据渥太华决策支持框架开发了一种决策辅助工具。结构开发过程涉及决策辅助工具开发者、专家反馈、德尔菲法的应用以及患者反馈。我们对34名局限性前列腺癌男性患者进行了试点测试。
该决策辅助工具是一本结构化手册。根据国际患者决策辅助标准清单,该决策辅助工具在27分中得22分(81.48%)。开发过程部分在24分中得22分(91.6%),决策过程有效性部分在6分中得6分(100%)。临床试点测试对该决策辅助工具的设计、图像、易懂性、可用性、解释及信息量给出了积极反馈。
我们开发了一种质量评分较高的西班牙语决策辅助工具,以帮助患者就其前列腺癌治疗做出明智选择。未来研究将评估该决策辅助工具的影响及其与改善决策制定的关联。
此工具提供了不同治疗方案的风险和益处信息,并帮助患者理解自身价值观对指导治疗选择的重要性。